Intranasal immunogenicity of a Deltacya Deltacrp-pabA mutant of Salmonella enterica serotype Typhimurium for the horse.
The aim of this study was to investigate the intranasal immunogenicity for the horse of a Deltacya Deltacrp-pabA mutant (MGN-707) of Salmonella enterica serotype Typhimurium (S. typhimurium). MGN-707 caused no sign of disease, was not detected in feces and a single administration induced strong Salmonella-specific serum and nasal mucosal antibody responses. All ponies had made strong salmonella specific serum IgGa, IgGb, IgA and IgM antibody responses by day 25 after the first immunization. IgM responses to salmonella lipopolysaccharide (LPS) were short lived whereas salmonella specific serum IgGa and IgGb persisted at high levels in all ponies until 83 and 140 days, respectively. Specific nasal mucosal antibody responses dominated by IgA and IgM were evident by day 25 in all ponies except one in which only specific IgGa and IgGb were evident. Specific nasal mucosal IgA persisted in most ponies until day 69. A second immunization on day 140 boosted antibody responses, and stimulated a strong nasal mucosal IgA response in the pony that failed to make an IgA response after primary immunization. At the termination of the experiment, IgA and IgGb dominated jejunal antibody responses whereas vaginal responses were mainly IgA. The latter response unequivocally confirms the existence of a common mucosal immune system in equids. The results indicate that a S. typhimurium Deltacya Deltacrp-pabA mutant has potential as an intranasal vaccine against salmonellosis in the horse.
Sheoran
A S
AS
Department of Veterinary Science, Gluck Equine Research Center, University of Kentucky, 40546-0099, Lexington, KY, USA
Timoney
J F
JF
Tinge
S A
SA
Sundaram
P
P
Curtiss
R
R
D000262:Adenylyl Cyclases / Q000235:genetics / Q000276:immunology; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000235:genetics; D001483:Base Sequence; D019755:Carbon-Carbon Lyases; D017931:DNA Primers / Q000235:genetics; D029968:Escherichia coli Proteins; D005243:Feces / Q000382:microbiology; D005260:Female; D017353:Gene Deletion; D005798:Genes, Bacterial; D006734:Horse Diseases / Q000276:immunology / Q000517:prevention & control; D006736:Horses; D018928:Immunity, Mucosal; D009154:Mutation; D011953:Receptors, Cyclic AMP / Q000235:genetics / Q000276:immunology; D012481:Salmonella Infections, Animal / Q000276:immunology / Q000517:prevention & control; D012486:Salmonella typhimurium / Q000235:genetics* / Q000276:immunology*; D000637:Transaminases; D014621:Vagina / Q000276:immunology
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D017931:DNA Primers; D029968:Escherichia coli Proteins; D011953:Receptors, Cyclic AMP; D000637:Transaminases; C000707653:aminodeoxychorismate synthase protein, E coli; D019755:Carbon-Carbon Lyases; D000262:Adenylyl Cyclases